Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Report Date: April 1, 2024
Reporting Period: This filing announces financial results for the three months and the full year ended December 31, 2023. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document referencing a press release. It does not contain specific numerical values for the following metrics:
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Investors must refer to Exhibit 99.1 (the press release) for specific financial figures.
Material Changes
The filing text does not explicitly detail material changes versus prior periods. It only confirms the issuance of results for the period ended December 31, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing is signed by Gregory A. Demopulos, M.D., President, CEO, and Chairman of the Board.
Legal Disclaimer: The report explicitly states that the information contained herein, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to liability under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933. Furthermore, this information shall not be incorporated by reference into any other SEC filing by Omeros Corporation.
Guidance and Risks: No specific forward-looking guidance, risk factors, or contingencies are detailed in this specific 8-K text.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) to obtain actual revenue, net loss, and cash position figures for Q4 and FY 2023.
- Verify the company's cash runway and burn rate, as these are critical for a biopharmaceutical firm not reporting specific liquidity numbers in this summary.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the company has provided updated full-year 2024 guidance in the referenced exhibit.